Antibody-based approaches have been widely used to target tumor cells via active targeting with specific drug carriers in cancer.86 Henry et al. used MLN2704, an antibody-chemotherapeutic conjugate consisting of a monoclonal antibody specific to PSMA conjugated to the drug maytansinoid 1 (DM1), which has microtubule-depolymerizing activity. The gene discussed is FOLH1; the disease is neoplasm.